Table 3.
Prognostic factors associated with overall mortality
| Variable | Comparison | Univariable | Multivariable | ||
|---|---|---|---|---|---|
|
|
|
||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age (years) | Per 1 increase | 1.02 (1.00-1.04) | 0.049 | 1.03 (1.01-1.05) | 0.020 |
| Sex | Male vs. Female | 1.12 (0.62-2.05) | 0.703 | ||
| Hypertension | Yes vs. No | 1.28 (0.79-2.06) | 0.317 | ||
| Diabetes mellitus | Yes vs. No | 1.16 (0.68-1.98) | 0.584 | ||
| BMI (kg/m2) | ≥ 23 vs. < 23 | 0.84 (0.50-1.39) | 0.491 | ||
| AFP (ng/mL) | ≥ 10 vs. < 10 | 2.37 (1.24-4.50) | 0.009 | 2.04 (1.06-3.91) | 0.033 |
| Platelet (103/µL) | < 150 vs. ≥ 150 | 2.07 (1.27-3.37) | 0.004 | ||
| Liver cirrhosis | Yes vs. No | 2.29 (1.39-3.78) | 0.001 | 2.10 (1.23-3.59) | 0.007 |
| HBV DNA (IU/mL) | ≥ 2000 vs. < 2000 | 1.49 (0.77-2.70) | 0.182 | ||
| NUCs treatment | Yes vs. No | 1.54 (0.97-2.47) | 0.069 | ||
| BCLC stage | A vs. 0 | 1.90 (1.02-3.52) | 0.043 | 1.99 (1.01-3.90) | 0.046 |
| Tumor size (cm) | ≥ 2 vs. < 2 | 1.65 (0.89-3.07) | 0.111 | ||
| Tumor number | Multiple vs. Single | 1.35 (0.74-2.46) | 0.332 | ||
| MVI | Yes vs. No | 1.82 (1.13-2.91) | 0.013 | ||
| MASLD | Yes vs. No | 0.57 (0.36-0.93) | 0.023 | 0.57 (0.34-0.95) | 0.030 |
HR, hazard ratio; CI, confidence interval; AFP, alpha fetoprotein; BMI, body mass index; NUCs, nucleos(t)ide analogs; MVI, microvascular invasion; MASLD, metabolic dysfunction-associated steatotic liver disease.